Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System
NCT ID: NCT03206814
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
480 participants
INTERVENTIONAL
2021-05-11
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypertension Registry of "Hypertension Prevention and Control Initiative in China"
NCT04289701
Efficiency of Monitoring and Control Program of Hypertension Through Pharmacy Offices. APOF Project
NCT02032472
Improve Hypertension Monitoring and Self-management by Using mHealth
NCT02632838
International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring
NCT02577835
Telemonitoring of Uncontrolled Hypertension
NCT02730052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. a new management strategy, named POST (i.e. "Patient Optimal Strategy for Treatment"), consisting in providing the patients with a system to communicate home blood pressure measurements to a referral centre, and the referral centre with an online platform to organize and easily interpret the information sent by patients and to monitor the patients' status;
2. usual care, consisting in regular visits at the referral centre.
Patients will be enrolled over 3 months and will be randomly allocated to one of the study groups. Follow-up phase will last 12 months after randomization and will focus on changes in ambulatory systolic BP (primary endpoint), in diastolic ambulatory BP, in office SBP and DBP, in Home SBP and DBP, in left ventricular mass index (LVMI) and urinary albumin excretion (UAE), all secondary end-points.
All patients will perform visits at baseline, three, six and twelve months. Physical examination, history of the patient and clinical blood pressure values will be obtained at every visit.
Echocardiogram, ECG, urine samples (UAE, urinary albumin/creatinine and 24-h ambulatory blood pressure monitoring (ABPM) will be performed at baseline, three months, six months and study end.
Blood samples (full blood count, creatinine, Na+, K+, fasting glucose, HbA1c, uric acid, lipids) will be performed at baseline; another blood sample will be collected at twelve months for measurement of serum creatinine (and renal function). UAE will be measured at baseline and study end, on morning urine samples.
Patients randomized to POST-strategy will measure Home BP two days a week (two measurements in the morning and two measurements in the evening) and communicate these values with the ESH CARE app; furthermore, before each visit they will measure their Home BP for 7 consecutive days (two measurements in the morning and two measurements in the evening), according to current guidelines on hypertension.
Patients randomized to usual care will also measure Home BP for 7 consecutive days at baseline and at study end, to provide a comparison. Operators (i.e. investigators dedicated to the follow-up of POST-strategy) will check these data organized by the POST system at least every 15 days, and adjust pharmacological therapy, if needed.
In patients randomized to usual care, therapy will be adjusted only at follow-up visits (i.e. at three and six months).
Pharmacological therapy will be increased or decreased according to blood pressure values; investigators may follow a therapy algorithm based on ESH/ESC guidelines, but are free to individualize it.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 - Usual care
Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
Usual care
Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
Group 2 - POST-strategy
Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
POST-strategy
Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Usual care
Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
POST-strategy
Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-80 years;
* Either the patient or another person close to him/her should possess a smartphone compatible with the ESH CARE app and be capable of using it;
* Uncontrolled (untreated or treated) hypertension, defined as office BP ≥140/90 mmHg, and Ambulatory 24h ABP ≥130/80 mmHg
Exclusion Criteria
* Severe uncontrolled hypertension (i.e. BP ≥200/120 mmHg despite treatment);
* Known secondary hypertension;
* Orthostatic hypotension (SBP fall \> 20 mmHg on standing);
* Unstable clinical conditions or severe disease with short life expectation;
* Known atrial fibrillation;
* Hepatic disease as determined by either AST or ALT values \> 2 times the upper limit of normal;
* History of gastrointestinal surgery or disorders which could interfere with drug absorption
* History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years;
* History of clinically significant autoimmune disorders such as systemic lupus erythematosus;
* History of drug or alcohol abuse within the last 5 years;
* History of non-compliance to medical regimens and/or patients who are considered potentially unreliable;
* Dementia (clinical diagnosis);
* Inability or unwillingness to give free informed consent;
* Inability to use even simple communication technologies;
* Pregnancy or planned pregnancy during study period
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Auxologico Italiano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gianfranco Parati, MD
Role: PRINCIPAL_INVESTIGATOR
Istituto Auxologico Italiano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Private Hospital " Dr Raúl Matera"
Bahía Blanca, , Argentina
Argerich Hospital
Buenos Aires, , Argentina
General San Martin Hospital of La Plata
La Plata, , Argentina
Spanish Hospital of Mendoza
Mendoza, , Argentina
British Sanatorium of Rosario
Rosario, , Argentina
Shanghai Institute of Hypertension
Shanghai, Huangpu, China
Jiangsu Province Official Hospital
Jiangse, , China
Ruijin Hospital North
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09A721
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.